Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

Pharmacopeia Elects to Expand Study to Include 1,000 mg Dose

PRINCETON, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Company's Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA), no safety or tolerability issues were observed with any of the doses under evaluation. As a result, the study will be expanded to include a 1,000 mg dose. This study designed to evaluate 14 days of daily dosing in healthy volunteers, has already completed evaluation of 50, 100, 250 and 500 mg doses of PS433540. The Company expects to report findings from the 1,000 mg dose later this year.

"The purpose of a multiple ascending dose study of this nature is to determine the maximally tolerated dose of a compound in healthy volunteers. Since we did not reach that threshold with this study's original four doses, we've decided to expand the trial and evaluate this fifth dose level," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "The fact that this compound appears safe and well tolerated at a wide dose range will provide added dosing flexibility for subsequent clinical trials."

In addition, results from the initial Phase 1 trial of PS433540, a single ascending dose (SAD) study, indicated that the compound was well tolerated at all six doses administered, while also suggesting that PS433540 possesses a half-life that is consistent with once daily oral administration.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being dev
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 ... DMPI) ("DelMar" "the Company") today announced the filing of ... recently changed its fiscal year end to June 30th ... common stock on a national securities exchange in the ... filed with the United States Securities Exchange Commission can ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... "Global Orthopedic Soft Tissue Repair Devices Market 2014-2018" ... soft tissues are the mass of cells that connect, ... orthopedic soft tissues such as tendons, ligaments, cartilage, fascia, ... the degeneration of these tissues with age result in ...
(Date:8/29/2014)... , Aug. 29, 2014 ... PHG AEX: PHIA) ... European Society of Cardiology (ESC) Congress ... highlighting the full range of its cardiology solutions serving clinicians ... from prevention and diagnosis, to ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... 26 Brainlab announced the availability of ExacTrac® Infrared Monitoring, ... during radiation therapy treatments, at the American Association of Physicists in ... , , ... tool used by many cancer care centers for patient setup; however, ...
... ,, ROCKVILLE, Md. , July 26 Sequella, Inc., ... announced today the publication of studies in the scientific journal Antimicrobial ... for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: ... Reddy, V.M., L. ...
Cached Medicine Technology:Brainlab Offers Real-Time Monitoring for IGRT 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 3
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
(Date:8/30/2014)... New Delhi, India (PRWEB) August 30, 2014 ... has introduced low cost SEO service for small businesses. ... businesses or start-ups cannot afford costly search engine optimization ... the budget of small businesses into account. , ... executive said, “We have introduced this low cost SEO ...
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... is a common problem millions of American cope with every day. ... nuisance, for some, it can have a crippling impact on social ... dramatic mood swings and depression. , Those struggling with acne ... In some cases, that can make the problem even worse. Instead ... a quest for clearer skin can now view acne treatment ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... with GlaxoSmithKline,s Advair and,Boehringer Ingelheim/Pfizer,s Spiriva, Significant ... According to a New Report from Decision ... Decision Resources, one of the,world,s leading research ... issues, finds that surveyed physicians indicate that ...
... Demand for Biotech-Based Materials, Fuel, ... ... (NYSE: DD ),today announced leadership changes to strengthen its leading ... based innovations in materials, food, feed and fuel markets., "Across ...
... Increased High-Performance ... and Academia, SOUTHPOINTE, Pa., Feb. 27 ... of simulation software and technologies,designed to optimize product ... Science and Technology Information (KISTI), one of,the world,s ...
... Delivery Plan Completely Customized for alli(R) ... ... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the power of technology ... the,immediate availability of its fresh meal delivery program specially,designed to coordinate ...
... Israel, Feb. 27 Shamir,Optical Industry Ltd. (Nasdaq: ... year end 2007 earnings results on Thursday, March 6, ... results at 9:00 A.M. EST,that morning., The conference ... To,listen live, please go to http://www.kcsa.com approximately ...
... with normal blood glucose (sugar) levels showed elevated markers for ... type 2 diabetes and cardiovascular disease, says a new study ... study, published in the March issue of Diabetes Care, is ... be at high risk for developing type 2 diabetes as ...
Cached Medicine News:Health News:A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 2Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 3Health News:DuPont Strengthens Leading Biotechnology Position with Leadership Changes 4Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 2Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 3Health News:KISTI Selects ANSYS as a Key Supplier in Engineering Simulation 4Health News:eDiets(R) Launches Fresh Meal Delivery Program for alli(R) Users 2Health News:eDiets(R) Launches Fresh Meal Delivery Program for alli(R) Users 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2007 Earnings Results 2Health News:Overweight Hispanic children shown to have vascular inflammation 2
... BD Beaver Clear Cornea Incision System ... specifically for the Cataract surgeon. The System ... an alternative to costly diamond knives. ... shield that is designed to both protects ...
... Built on the market leading optical ... 500 has been optimized for even better ... illumination system, including a new XHL Xenon ... the cornea and clear, high resolution images ...
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D...
... the EZ Meter and press the measurement ... measurement results on its large color LCD ... printout makes this the ideal instrument for ... addition to being extremely easy-to-use, the EZ-200 ...
Medicine Products: